ArticleOncology letters2026
Comprehensive bioinformatics analysis of NCAPH expression and its clinical importance in endometrial cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence has implicated non-SMC condensin I complex subunit H (NCAPH) as a key regulator of mitosis and driver of tumorigenesis. However, its expression profiling and clinical relevance in endometrial cancer (EC) remain inadequately characterized. The present study aimed to systematically investigate the expression profiling, mutational landscape, co-expression networks and prognostic importance of NCAPH in EC through integrated bioinformatics approaches. NCAPH expression was evaluated in pan-cancer and EC cohorts derived from The Cancer Genome Atlas and Genotype Tissue Expression databases. Mutational analysis was performed using the 'maftools' package in R software. Genes co-expressed with NCAPH (with a significance threshold of P<0.05) were subjected to functional enrichment analysis using Metascape. Single-sample Gene Set Enrichment Analysis (ssGSEA) was used to evaluate the correlation between gene expression and pathway scores. The Tumor Immune Estimation Resource database was utilized to explore the correlation between NCAPH expression and the abundance of tumor-infiltrating immune cells in EC. The prognostic importance of NCAPH was assessed by Kaplan-Meier survival analysis and receiver operating characteristic curve analysis. Immunohistochemistry and western blotting was performed to validate NCAPH protein expression in clinical specimens. Results indicated that NCAPH mRNA and protein expression were significantly elevated in EC compared with normal endometrium. In addition, NCAPH expression was found to be positively correlated with advanced International Federation of Gynecology and Obstetrics stage, advanced age, TP53 mutation and aggressive histological subtypes. Somatic mutations of NCAPH occurred in 4.92% of EC cases, with missense mutations being the predominant type (79.3%). Functional enrichment analysis indicated that NCAPH-associated genes were involved in 'cell cycle', 'DNA replication' and 'oocyte meiosis'. ssGSEA exhibited a positive correlation between NCAPH and DNA repair, G
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.